ATE217197T1 - Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa - Google Patents

Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa

Info

Publication number: ATE217197T1
Authority: AT; Austria
Prior art keywords: hyaluronic acid; pct; nsaid; mucosa; diseases
Prior art date: 1995-07-18

Application number

AT96922722T

Other languages

English (en)

Inventor

Samuel Simon Asculai

Rudolf Edgar Falk

Alan Russell

Original Assignee

Jagotec Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-18

Filing date

1996-07-18

Publication date

2002-05-15

1996-07-18 Application filed by Jagotec Ag filed Critical Jagotec Ag

2002-05-15 Application granted granted Critical

2002-05-15 Publication of ATE217197T1 publication Critical patent/ATE217197T1/de

Links

KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title abstract 3
229920002674 hyaluronan Polymers 0.000 title abstract 3
229960003160 hyaluronic acid Drugs 0.000 title abstract 3
201000010099 disease Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
229940126601 medicinal product Drugs 0.000 title 1
210000004877 mucosa Anatomy 0.000 title 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title 1
239000012634 fragment Substances 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
210000004400 mucous membrane Anatomy 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000008733 trauma Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Inorganic Chemistry (AREA)
Rheumatology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT96922722T 1995-07-18 1996-07-18 Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa ATE217197T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CA002154103A CA2154103C (en)	1995-07-18	1995-07-18	Treatment of mucous membrane disease, trauma or condition and for the relief of pain
PCT/CA1996/000488 WO1997003699A1 (en)	1995-07-18	1996-07-18	Use of hyaluronic acid and a nsaid for the manufacture of a medicament for the treatment of mucosal diseases

Publications (1)

Publication Number	Publication Date
ATE217197T1 true ATE217197T1 (de)	2002-05-15

Family

ID=4156246

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96922722T ATE217197T1 (de)	1995-07-18	1996-07-18	Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa

Country Status (10)

Country	Link
US (1)	US6159955A (de)
EP (1)	EP0839052B1 (de)
JP (1)	JP4194653B2 (de)
AT (1)	ATE217197T1 (de)
AU (1)	AU719257B2 (de)
CA (1)	CA2154103C (de)
DE (1)	DE69621132T2 (de)
ES (1)	ES2176468T3 (de)
NZ (1)	NZ312073A (de)
WO (1)	WO1997003699A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6875753B1 (en)	1996-03-14	2005-04-05	The Governors Of The University Of Alberta	Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US6958148B1 (en)	1998-01-20	2005-10-25	Pericor Science, Inc.	Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en)	1998-01-20	2005-07-19	Pericor Science, Inc.	Conjugates of agents and transglutaminase substrate linking molecules
US5981499A (en) *	1998-02-20	1999-11-09	Atlantic Biomed Corporation	Lesion-directed antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa
JP4685242B2 (ja) *	1998-10-22	2011-05-18	バイオニケ・テオランタ	ヒアルロン酸を用いた放射線膀胱炎の予防、軽減、および治療法
US7635489B2 (en) *	2001-05-18	2009-12-22	Leneau Holdings, Llc	Ingestion of hyaluronic acid for improved joint health
US6607745B2 (en)	2001-05-18	2003-08-19	Harry Leneau	Ingestion of hyaluronic acid for improved joint function and health
ITBO20010361A1 (it) *	2001-06-07	2002-12-07	Farma Derma S R L	Uso di acido ialuronico per la produzione di un preparato ad uso vaginale, in particolare per la cura degli stati atrofici e distrofici cerv
JP2005526114A (ja) *	2002-05-06	2005-09-02	コッラジェネックスファーマシューチカルスインコーポレイテッド	粘膜炎及び真菌感染症の同時治療方法
TR200201556A2 (tr) *	2002-06-12	2004-01-21	Orva İlaç Sanayi̇ Ve Ti̇caret A. Ş.	Kortikosteroid ve nonsteroidal antienflamatuar içeren farmasötik bileşim
US8129359B2 (en) *	2004-06-04	2012-03-06	Ethicon, Inc.	Composition and method for treating post-surgical pain
US8377906B2 (en) *	2004-06-04	2013-02-19	Ethicon, Inc.	Compositions and methods for preventing or reducing postoperative ileus and gastric stasis
CN101522164B (zh)	2006-09-13	2014-03-26	提升肤质产品公司	用于治疗皮肤的化妆品组合物及其方法
WO2008145149A1 (en) *	2007-05-28	2008-12-04	Vincenzo Massimo Lombardo	Antiphlogistic and analgesic composition for topical use in a region of an animal locomotive system
GB0817208D0 (en) *	2008-09-19	2008-10-29	Pimco 2664 Ltd	Therapeutic apsap compounds and their use
IT1401351B1 (it) *	2010-07-28	2013-07-18	Galsor S R L	Composizione farmaceutica a base di una o più frazioni di acido ialuronico o suoi sali in associazione con un inibitore della ialuronidasi e suoi usi in campo medico
ES2667854T3 (es)	2011-07-07	2018-05-14	Holy Stone Healthcare Co., Ltd.	Composición para uso en el tratamiento y la prevención de trastornos relacionados con la inflamación
ES2665254T3 (es)	2011-07-12	2018-04-25	Holy Stone Healthcare Co., Ltd.	Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas
JPWO2016153015A1 (ja) *	2015-03-25	2018-05-10	株式会社ファルマクリエ神戸	高分子薬効成分を含有した口腔内施用物および口腔内への高分子薬効成分の投与方法
US11793783B2 (en)	2015-08-05	2023-10-24	Cmpd Licensing, Llc	Compositions and methods for treating an infection
US11446236B2 (en)	2015-08-05	2022-09-20	Cmpd Licensing, Llc	Topical antimicrobial compositions and methods of formulating the same
US11684567B2 (en) *	2015-08-05	2023-06-27	Cmpd Licensing, Llc	Compositions and methods for treating an infection
US11633352B2 (en)	2018-01-09	2023-04-25	E2Bio Life Science, LLC	Diclofenac and hyaluronic acid combination treatment for oral leukpoplakia
WO2020117546A1 (en) *	2018-12-03	2020-06-11	Samuel Asculai	Pharmaceutical formulations and compositions suitable to treat mucositis
WO2020160344A1 (en) *	2019-02-01	2020-08-06	Ehrenpreis Eli D	Diclofenac and hyaluronic acid combination treatment for oral leukpoplakia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4141973A (en) *	1975-10-17	1979-02-27	Biotrics, Inc.	Ultrapure hyaluronic acid and the use thereof
IT1229075B (it) *	1985-04-05	1991-07-17	Fidia Farmaceutici	Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
EP0138572B1 (de) *	1983-10-11	1990-07-25	FIDIA S.p.A.	Fraktionen von Hyaluronsäure mit pharmazeutischer Aktivität, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
US5202431A (en) *	1985-07-08	1993-04-13	Fidia, S.P.A.	Partial esters of hyaluronic acid
JPS63101332A (ja) *	1986-10-17	1988-05-06	Sato Seiyaku Kk	経口投与用徐放性製剤
CA1340994C (en) *	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Treatment of conditions and disease
JP2951681B2 (ja) *	1990-02-23	1999-09-20	株式会社資生堂	経粘膜投与用薬剤組成物
CA2061703C (en) *	1992-02-20	2002-07-02	Rudolf E. Falk	Formulations containing hyaluronic acid
CA2061566C (en) *	1992-02-20	2002-07-09	Rudolf E. Falk	Treatment of disease employing hyaluronic acid and nsaids
US5910489A (en) *	1990-09-18	1999-06-08	Hyal Pharmaceutical Corporation	Topical composition containing hyaluronic acid and NSAIDS
US6017900A (en) *	1991-07-03	2000-01-25	Hyal Pharmaceutical Corporation	Topical composition containing hyaluronic acid and nsaids
CA2094203A1 (en) *	1993-04-16	1994-10-17	Derek A. Willoughby	Inhibition of angiogenesis
JPH0717870A (ja) *	1993-06-29	1995-01-20	Toshiko Yamamoto	トローチ剤

1995
- 1995-07-18 CA CA002154103A patent/CA2154103C/en not_active Expired - Lifetime
1996
- 1996-07-18 US US08/981,602 patent/US6159955A/en not_active Expired - Lifetime
- 1996-07-18 JP JP50612097A patent/JP4194653B2/ja not_active Expired - Fee Related
- 1996-07-18 NZ NZ312073A patent/NZ312073A/en not_active IP Right Cessation
- 1996-07-18 DE DE69621132T patent/DE69621132T2/de not_active Expired - Lifetime
- 1996-07-18 WO PCT/CA1996/000488 patent/WO1997003699A1/en not_active Ceased
- 1996-07-18 AU AU63519/96A patent/AU719257B2/en not_active Expired
- 1996-07-18 EP EP96922722A patent/EP0839052B1/de not_active Expired - Lifetime
- 1996-07-18 AT AT96922722T patent/ATE217197T1/de active
- 1996-07-18 ES ES96922722T patent/ES2176468T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2176468T3 (es)	2002-12-01
EP0839052B1 (de)	2002-05-08
US6159955A (en)	2000-12-12
EP0839052A1 (de)	1998-05-06
CA2154103C (en)	1998-02-24
AU719257B2 (en)	2000-05-04
WO1997003699A1 (en)	1997-02-06
NZ312073A (en)	2000-02-28
AU6351996A (en)	1997-02-18
JP4194653B2 (ja)	2008-12-10
CA2154103A1 (en)	1997-01-19
JPH11514967A (ja)	1999-12-21
DE69621132D1 (de)	2002-06-13
DE69621132T2 (de)	2002-10-31

Similar Documents

Publication	Publication Date	Title
ATE217197T1 (de)	2002-05-15	Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
DE69507029D1 (de)	1999-02-11	Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
ATE144420T1 (de)	1996-11-15	Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69526937D1 (de)	2002-07-11	Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE69636343D1 (de)	2006-08-24	Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ATE213164T1 (de)	2002-02-15	Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
DE69903750D1 (de)	2002-12-05	Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
ATE146677T1 (de)	1997-01-15	Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
ATE309795T1 (de)	2005-12-15	Acetylcholinesteraseinhibitoren zur behandlung und diagnose von atemstörungen während des schlafes
DE69725879D1 (de)	2003-12-04	VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
DE69911380D1 (de)	2003-10-23	Verwendung von isatin- und oxindolderivaten zur herstellung von arzeneimittel für die behandlung von mykobakteriellen erkrankungen
DE59508961D1 (de)	2001-02-15	Verwendung von weihrauch zur behandlung der alzheimer-krankheit
ATE353645T1 (de)	2007-03-15	Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
DE69821655D1 (de)	2004-03-18	Verwendung von phospholipiden zur herstellung eines arzneimittels zur vorbeugung von adhäsionen
FI971127A0 (fi)	1997-03-18	2,4-diaminopyrimidiini-3-oksidin tai jonkin sen suolan käyttö kollageenin kypsymis- ja rakentumishäiriöiden hoitamiseen
ATE217191T1 (de)	2002-05-15	Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE191342T1 (de)	2000-04-15	Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
HUP9902135A2 (hu)	1999-11-29	(+)-alfa-(2,3-Dimetoxi-fenil)-1-[2-(4-fluor-fenil)-etil]-4-piperidin-metanol alkalmazása depresszív és bipoláris rendellenességek kezelésére alkalmas gyógyszerkészítmény előállítására
DE69531150D1 (de)	2003-07-31	Verwendung von biopolymeren zur behandlung der muskeln
ATE194076T1 (de)	2000-07-15	Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE69329687D1 (de)	2000-12-21	Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus
ATE213634T1 (de)	2002-03-15	Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
DE69421705D1 (de)	1999-12-23	Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
DE69424415D1 (de)	2000-06-15	Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE312611T1 (de)	2005-12-15	Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen